Side effects and watch-outs
- UTI risk
- Genital yeast infections
- DKA (rare — more risk in T1D)
- Increased urination
- Dehydration
- Fournier's gangrene (rare but serious)
- Limb amputation risk (canagliflozin — less with empa)
Medication / SGLT2/Cardiovascular
Empagliflozin (Jardiance)
SGLT2 inhibitor — reduces glucose by blocking kidney reabsorption. Dramatic cardiovascular and renal protective benefits beyond glucose control. Reduces heart failure hospitalizations and cardiovascular death. Growing use in longevity protocols for cardiometabolic health.
Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.